blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2920178

EP2920178 - NOVEL HETEROCYCLIC DERIVATIVES AS MODULATORS OF KINASE ACTIVITY (P70S6 AND AKT) [Right-click to bookmark this link]
Former [2015/39]NOVEL HETEROCYCLIC DERIVATIVES AS MODULATORS OF KINASE ACTIVITY
[2016/24]
StatusNo opposition filed within time limit
Status updated on  27.10.2017
Database last updated on 15.06.2024
FormerThe patent has been granted
Status updated on  18.11.2016
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Merck Patent GmbH
Frankfurter Strasse 250
64293 Darmstadt / DE
[2015/39]
Inventor(s)01 / LAN, Ruoxi
204 Clocktower Drive Unit 6309
Waltham, Massachusetts 02452 / US
02 / HUCK, Bayard R.
50 Woodmere Drive
Sudbury, Massachusetts 01776 / US
03 / CHEN, Xiaoling
250 Hammond Pond Pkwy U906S
Chestnut Hill, Massachusetts 02467 / US
04 / XIAO, Yufang
11 Ames Avenue
Lexington, Massachusetts 02421 / US
 [2015/39]
Application number, filing date13802772.715.11.2013
[2015/39]
WO2013US70261
Priority number, dateUS201261727298P16.11.2012         Original published format: US 201261727298 P
[2015/39]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014078637
Date:22.05.2014
Language:EN
[2014/21]
Type: A1 Application with search report 
No.:EP2920178
Date:23.09.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 22.05.2014 takes the place of the publication of the European patent application.
[2015/39]
Type: B1 Patent specification 
No.:EP2920178
Date:21.12.2016
Language:EN
[2016/51]
Search report(s)International search report - published on:EP22.05.2014
ClassificationIPC:C07D487/04, A61K31/505, A61P35/00
[2015/39]
CPC:
C07D498/04 (EP,CN,US); C07D239/70 (EP,CN,US); A61K31/496 (EP,CN,US);
A61K31/517 (EP,CN,US); A61K31/519 (EP,CN,US); A61K31/5383 (EP,CN,US);
A61K45/06 (US); A61N5/10 (US); A61P15/00 (EP);
A61P17/06 (EP); A61P19/02 (EP); A61P25/28 (EP);
A61P27/02 (EP); A61P27/06 (EP); A61P29/00 (EP);
A61P31/04 (EP); A61P35/00 (EP); A61P9/10 (EP);
C07D471/04 (EP,CN,US); C07D475/06 (EP,US); C07D487/04 (EP,CN,US);
A61N2005/1098 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/39]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:NEUARTIGE HETEROCYCLISCHE DERIVATE ALS KINASEAKTIVITÄTSMODULATOREN (P70S6 UND AKT)[2016/24]
English:NOVEL HETEROCYCLIC DERIVATIVES AS MODULATORS OF KINASE ACTIVITY (P70S6 AND AKT)[2016/24]
French:NOUVEAUX DÉRIVÉS HÉTÉROCYCLIQUES COMME MODULATEURS DE L'ACTIVITÉ KINASE (P70S6 UND AKT)[2016/24]
Former [2015/39]NEUARTIGE HETEROCYCLISCHE DERIVATE ALS KINASEAKTIVITÄTSMODULATOREN
Former [2015/39]NOVEL HETEROCYCLIC DERIVATIVES AS MODULATORS OF KINASE ACTIVITY
Former [2015/39]NOUVEAUX DÉRIVÉS HÉTÉROCYCLIQUES COMME MODULATEURS DE L'ACTIVITÉ KINASE
Entry into regional phase22.05.2015National basic fee paid 
22.05.2015Designation fee(s) paid 
22.05.2015Examination fee paid 
Examination procedure22.05.2015Examination requested  [2015/39]
29.02.2016Amendment by applicant (claims and/or description)
09.06.2016Communication of intention to grant the patent
27.09.2016Fee for grant paid
27.09.2016Fee for publishing/printing paid
27.09.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  09.06.2016
Opposition(s)22.09.2017No opposition filed within time limit [2017/48]
Fees paidRenewal fee
10.11.2015Renewal fee patent year 03
10.11.2016Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.11.2013
AL21.12.2016
AT21.12.2016
BE21.12.2016
CY21.12.2016
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
MK21.12.2016
NL21.12.2016
PL21.12.2016
RO21.12.2016
RS21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
SM21.12.2016
TR21.12.2016
BG21.03.2017
NO21.03.2017
GR22.03.2017
IS21.04.2017
PT21.04.2017
[2020/34]
Former [2020/15]HU15.11.2013
AT21.12.2016
BE21.12.2016
CY21.12.2016
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
MK21.12.2016
NL21.12.2016
PL21.12.2016
RO21.12.2016
RS21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
SM21.12.2016
TR21.12.2016
BG21.03.2017
NO21.03.2017
GR22.03.2017
IS21.04.2017
PT21.04.2017
Former [2019/51]HU15.11.2013
AT21.12.2016
BE21.12.2016
CY21.12.2016
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
MK21.12.2016
NL21.12.2016
PL21.12.2016
RO21.12.2016
RS21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
SM21.12.2016
BG21.03.2017
NO21.03.2017
GR22.03.2017
IS21.04.2017
PT21.04.2017
Former [2019/47]HU15.11.2013
AT21.12.2016
BE21.12.2016
CY21.12.2016
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
NL21.12.2016
PL21.12.2016
RO21.12.2016
RS21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
SM21.12.2016
BG21.03.2017
NO21.03.2017
GR22.03.2017
IS21.04.2017
PT21.04.2017
Former [2019/31]HU15.11.2013
AT21.12.2016
BE21.12.2016
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
NL21.12.2016
PL21.12.2016
RO21.12.2016
RS21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
SM21.12.2016
BG21.03.2017
NO21.03.2017
GR22.03.2017
IS21.04.2017
PT21.04.2017
Former [2018/33]AT21.12.2016
BE21.12.2016
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
MC21.12.2016
NL21.12.2016
PL21.12.2016
RO21.12.2016
RS21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
SM21.12.2016
BG21.03.2017
NO21.03.2017
GR22.03.2017
IS21.04.2017
PT21.04.2017
Former [2018/14]AT21.12.2016
BE21.12.2016
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
NL21.12.2016
PL21.12.2016
RO21.12.2016
RS21.12.2016
SE21.12.2016
SI21.12.2016
SK21.12.2016
SM21.12.2016
BG21.03.2017
NO21.03.2017
GR22.03.2017
IS21.04.2017
PT21.04.2017
Former [2018/01]AT21.12.2016
BE21.12.2016
CZ21.12.2016
DK21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
NL21.12.2016
PL21.12.2016
RO21.12.2016
RS21.12.2016
SE21.12.2016
SK21.12.2016
SM21.12.2016
BG21.03.2017
NO21.03.2017
GR22.03.2017
IS21.04.2017
PT21.04.2017
Former [2017/41]AT21.12.2016
BE21.12.2016
CZ21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
NL21.12.2016
PL21.12.2016
RO21.12.2016
RS21.12.2016
SE21.12.2016
SK21.12.2016
SM21.12.2016
BG21.03.2017
NO21.03.2017
GR22.03.2017
IS21.04.2017
PT21.04.2017
Former [2017/36]BE21.12.2016
CZ21.12.2016
EE21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
NL21.12.2016
PL21.12.2016
RO21.12.2016
RS21.12.2016
SE21.12.2016
SK21.12.2016
NO21.03.2017
GR22.03.2017
IS21.04.2017
Former [2017/34]CZ21.12.2016
FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
NL21.12.2016
RS21.12.2016
SE21.12.2016
NO21.03.2017
GR22.03.2017
Former [2017/31]FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
NL21.12.2016
RS21.12.2016
SE21.12.2016
NO21.03.2017
GR22.03.2017
Former [2017/28]FI21.12.2016
HR21.12.2016
LT21.12.2016
LV21.12.2016
RS21.12.2016
SE21.12.2016
NO21.03.2017
GR22.03.2017
Former [2017/12]LV21.12.2016
Cited inInternational search[A]WO2007072017  (CHROMA THERAPEUTICS LTD [GB], et al) [A] 1-10* the whole document *;
 [A]WO2008075109  (ASTEX THERAPEUTICS LTD [GB], et al) [A] 1-10 * the whole document *;
 [A]WO2010056563  (LILLY CO ELI [US], et al) [A] 1-10 * the whole document *
by applicantWO03064397
 WO2004092154
 WO2005033086
 WO2005039506
 WO2005054237
 WO2005056014
 WO2005117909
 WO2006071819
 WO2006120573
 WO2006131835
 WO2006136821
 WO2008140947
 WO2010056563
 WO2010093419
 WO2012013282
 WO2012016001
 WO2012069146
 WO2013040044
    - HANKS, S.K.; HUNTER, T., FASEB J., (1995), vol. 9, pages 576 - 596
    - KNIGHTON ET AL., SCIENCE, (1991), vol. 253, pages 407 - 414
    - HILES ET AL., CELL, (1992), vol. 70, pages 419 - 429
    - KUNZ ET AL., CELL, (1993), vol. 73, pages 585 - 596
    - GARCIA-BUSTOS ET AL., EMBO J., (1994), vol. 13, pages 2352 - 2361
    - CANCER RES., (1999), vol. 59, pages 1408 - 11
    - M. BARLUND; O. MONNI; J. KONONEN; R. CORNELISON; J. TORHORST; G. SAUTER; O.=P. KALLIONIEML; KALLIONIEMI A., CANCER RES., (2000), vol. 60, pages 5340 - 5346
    - CANCER RES., (2000), vol. 60, pages 5371 - 5375
    - HOUBEN-WEYL, Methoden der organischen Chemie, GEORG-THIEME-VERLAG
    - HANZLIK ET AL., J. ORG. CHEM., (1990), vol. 55, pages 3992 - 3997
    - REIDER ET AL., J. ORG. CHEM., (1987), vol. 52, pages 3326 - 3334
    - FOSTER, ADV. DRUG RES., (1985), vol. 14, pages 1 - 40
    - GILLETTE ET AL., BIOCHEMISTRY, (1994), vol. 33, no. 10, pages 2927 - 2937
    - JARMAN ET AL., CARCINOGENESIS, (1993), vol. 16, no. 4, pages 683 - 688
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.